Frontage Achieves Three Successful FDA Inspections in 2025 with NAI Classification
EXTON, PA., September 29, 2025 – We are pleased to announce the following Frontage facilities recently completed inspections by the U.S. Food and Drug Administration (FDA). All inspections concluded with a No Action Indicated (NAI) classification , which means FDA identified no objectionable conditions.
Toxicology Services, Concord OH, 21-25 July 2025
Bioanalytical Services, Exton PA, 02-05 September 2025
Clinical Services, Secaucus NJ, 08-11 September 2025
“This outstanding accomplishment is a true testament to the robust quality system we have built at Frontage,” said Dr. John Lin, Co-CEO, “the excellence in science that guides our daily work, and the dedication of our technical and QA teams.”
At Frontage, we remain committed to supporting our clients with services that meet rigorous regulatory expectations and ensure confidence in every project we undertake. By achieving consecutive FDA inspections with no adverse findings, Frontage reinforces its position as a reliable partner for clients seeking regulatory assurance and operational excellence. For clients, this means fewer surprises, better planning, and greater confidence when pursuing high-stakes submissions.
To learn more about our quality systems, please visit: https://www.frontagelab.com/about/quality-assurance/